Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
F8 encodes coagulation factor VIII, which participates in the intrinsic pathway of blood coagulation\; factor VIII is a cofactor for factor IXa which, in the presence of Ca+2 and phospholipids, converts factor X to the activated form Xa. Zusätzlich bieten wir Ihnen Factor VIII Antikörper (341) und Factor VIII Proteine (22) und viele weitere Produktgruppen zu diesem Protein an.
Showing 10 out of 63 products:
Human Factor VIII ELISA Kit für Sandwich ELISA - ABIN456987
Wang, Yuan, Zhong, Wen, Deng, Liang, Zheng: The anticoagulant effect of PGI2S and tPA in transgenic umbilical vein endothelial cells is linked to up-regulation of PKA and PKC. in International journal of molecular sciences 2014
Show all 2 Pubmed References
gene is flanked by factor VII (zeige TH ELISA Kits) and factor X genes; gene encodes a protein homologous to factor VII (zeige TH ELISA Kits), but lacks critical residues for factor VII (zeige TH ELISA Kits) activity; functions as an inhibitor of blood coagulation in biochemical assays using zebrafish or human plasmas
CD32 blockade suppresses the FVIII-specific recall response by two ways: i) increasing apoptosis of FVIII-specific memory B-cells and ii) disturbing FVIII-specific T cell response by modulating presentation of rhFVIII to CD4(+) T cells.
Type 2N von Willebrand disease variants were associated with decreased VWF (zeige VWF ELISA Kits) secretion and impaired factor VIII binding/stability.
Cytokine release was quantified from FVIII(-/-) splenocytes restimulated with FVIII in the absence or presence of different anti-FcgammaRIIB (CD32) Antibodies (anti-CD32 mAbs) over 6 days.
results revealed localized vascular expression of FVIII and von Willebrand factor (zeige VWF ELISA Kits) and identified lymphatic endothelial cell as a major cellular source of FVIII in extrahepatic tissues.
the results indicate that residues in the C1 and/or C2 domains of factor VIII are implicated in immunogenic factor VIII uptake, at least in vitro Conversely, in vivo, the binding to endogenous von Willebrand factor (zeige VWF ELISA Kits) masks the reducing effect of mutations in the C domains on factor VIII immunogenicity.
data demonstrate that infusion of platelets containing FVIII triggers neither primary nor memory anti-FVIII immune response in FVIII(null) mice
Both platelet-VWF (zeige VWF ELISA Kits) and plasma-VWF (zeige VWF ELISA Kits) are required for optimal platelet-derived FVIII gene therapy for hemophilia A in the presence of inhibitors.
These data support the investigation of FVIII orthologs as treatment modalities in both the congenital and acquired FVIII inhibitor settings.
Activatable bioengineered FIX molecules with FVIII-independent activity might be a promising tool for improving hemophilia A treatment, especially for patients with inhibitors.
This study demonstrated that FVIIIa interacts with Low-density lipoprotein receptor-related protein 1 (zeige LRP1 ELISA Kits) cluster III.
Human FVIII gene transfer without in vivo selection of manipulated cells can introduce immune tolerance in hemophilia A mice and this immune tolerance is CD4 (zeige CD4 ELISA Kits)(+) T cell mediated.
High dose of rhFVIII induces apoptosis in FVIII-specific memory B-cells but does not influence FVIII-specific T cell response.
Case Report: complex recombination with deletion in the F8 and duplication in the TMLHE (zeige TMLHE ELISA Kits) mediated by int22h copies during early embryogenesis in proband's mother.
Report a diagnostic algorithm that can reliably identify pathogenic variants of factor 8/9 and von Willebrand factor (zeige VWF ELISA Kits) and diagnose patients with hemophilia A, hemophilia B or von Willebrand disease.
Each hFVIII vector was administered to FVIII knockout (KO) mice at a dose of 10(10) genome copies (GC) per mouse. Criteria for distinguishing the performance of the different enhancer/promoter combinations were established prior to the initiation of the studies.
Relevance of ethnic differences in factor XIII (zeige UGDH ELISA Kits) activity on laboratory reference ranges.
analysis of co-existing variants in both F8 and PTGS-1 (zeige PTGS1 ELISA Kits) genes in a three-generation pedigree of hemophilia A
FVIII endocytosis is driven by interaction with LRP1 (zeige LRP1 ELISA Kits)
A coagulation initiating pathway is revealed in which the TF-FVIIa-nascent FXa (zeige F10 ELISA Kits) complex activates FVIII apart from thrombin (zeige F2 ELISA Kits) feedback.
An in silico and in vitro approach to elucidate the impact of residues flanking the cleavage scissile bonds of FVIII by thrombin (zeige F2 ELISA Kits) has been presented.
It was concluded that VEGF (zeige VEGFA ELISA Kits) and factor VIII are important growth factors associated with fetal development in pigs and are identified in all uterine segments.
thrombin (zeige F2 ELISA Kits) stimulates transglutaminase activity in articular cartilage by directly cleaving factor XIII (zeige UGDH ELISA Kits) and by receptor-mediated up-regulation of factor XIII (zeige UGDH ELISA Kits) synthesis
cupredoxin-like A1 subdomains in fVIII contain inter-species differences that are a result of selective pressure on the dissociation rate constant
Factor VIIIc is responsible for tissue invasion during tumor progression.
This gene encodes coagulation factor VIII, which participates in the intrinsic pathway of blood coagulation\; factor VIII is a cofactor for factor IXa which, in the presence of Ca+2 and phospholipids, converts factor X to the activated form Xa. This gene produces two alternatively spliced transcripts. Transcript variant 1 encodes a large glycoprotein, isoform a, which circulates in plasma and associates with von Willebrand factor in a noncovalent complex. This protein undergoes multiple cleavage events. Transcript variant 2 encodes a putative small protein, isoform b, which consists primarily of the phospholipid binding domain of factor VIIIc. This binding domain is essential for coagulant activity. Defects in this gene results in hemophilia A, a common recessive X-linked coagulation disorder.
, procoagulant component
, antihemophilic factor
, coagulation factor VIII
, coagulation factor VIIIc
, factor VIII F8B
, coagulation factor VIII, procoagulant component (hemophilia A)
, factor VIII
, coagulation co-factor